The Ideal Clinical Trials Research Site
Mark Prussian – CEO Mark M. Prussian is a board-certified healthcare administrator and Chief Executive Officer of The Eye Care Institute. Prussian has served as CEO since 1995 and is…
-
-
Butchertown Clinical Trials and The Eye Care Institute Announce Our 14th FDA Approval Tyrvaya™, the first and only nasal spray approved for signs and symptoms of Dry Eye Disease – Second Announcement in Two Days
October 19, 2021 For Immediate Release Oyster Point Pharma, a Princeton NJ company, has announced the FDA has approved Tyrvaya™ as the first and only nasal spray approved for treating…
-
Butchertown Clinical Trials and The Eye Care Institute Announce Our 13th FDA Approval Dextenza®, physician-inserted eye allergy treatment lasting up to 30 days
October 18, 2021 For Immediate Release Ocular Therapeutix, a Bedford MA company, has announced the FDA has approved Dextenza® for treating ocular itching associated with allergic conjunctivitis. John C. Meyer,…
-
Health care research facility opens in Butchertown
The Eye Care Institute opened a new research facility on its Butchertown campus. Butchertown Clinical Trials, a division of the Eye Care Institute, announced Friday that the $1.8 million stand-alone…
-
Stuart Urbach in Memorium
Stuart Urbach, MD1925 – 2021In Memory Patients, physicians, friends, and co-workers of Dr. Stuart Urbach have lost a giant upon his passing. Dr. Urbach graduated medical school at the University…
